A Drug Medicine Didn't Expect
Ketamine was not developed as an antidepressant.
It entered American medicine more than half a century ago as an anesthetic.
Then researchers discovered something unexpected.
At doses used in psychiatric research, ketamine could sometimes reduce severe depressive symptoms remarkably quickly—including in people who had not responded adequately to conventional treatments.
The finding challenged one of psychiatry's longstanding assumptions.
Antidepressant medications traditionally required weeks before substantial benefits were expected.
Ketamine suggested that meaningful changes in mood could sometimes occur within hours or days.
That discovery opened another question.
If ketamine could influence depression through mechanisms substantially different from traditional antidepressants, what else might it affect?
Researchers began investigating PTSD.
OCD.
Addiction.
Anxiety.
Eating disorders.
Sleep.
Chronic pain.
And, increasingly, neurological and neurodegenerative conditions.
The result is an unusual scientific landscape.
Ketamine has meaningful human clinical evidence in some areas.
Preliminary signals in others.
And intriguing animal or mechanistic research in still others.
The mistake is treating all three as equivalent.
They aren't.
First: Ketamine Is Not Spravato
Public discussions frequently use ketamine, esketamine and Spravato interchangeably.
They are related.
They are not identical.
Racemic ketamine contains two mirror-image molecular forms, or enantiomers: R-ketamine and S-ketamine.
Ketamine hydrochloride has been FDA-approved in the United States since 1970 as a general anesthetic.
Its FDA labeling does not include depression or another psychiatric disorder.
When racemic ketamine is administered for psychiatric treatment in the United States, that use is therefore off-label.
Esketamine is the S-enantiomer of ketamine.
The intranasal esketamine product Spravato has separate FDA approval.
As of 2026, Spravato is approved for treatment-resistant depression in adults either as monotherapy or together with an oral antidepressant. It is also approved, together with an oral antidepressant, for depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior.
That distinction matters throughout this article.
Evidence involving one formulation, route or indication cannot automatically be generalized to another.
Depression Changed Everything
The strongest modern psychiatric evidence for racemic ketamine concerns depression, particularly treatment-resistant depression.
Multiple randomized trials and subsequent systematic reviews have documented rapid antidepressant effects after intravenous ketamine.
Modern evidence also supports intranasal esketamine for treatment-resistant depression, leading to its FDA approval.
A 2025 systematic review and meta-analysis comparing IV racemic ketamine with esketamine found broadly comparable acute response and remission rates in the available studies, although most head-to-head evidence was observational rather than randomized.
But one feature remains particularly important:
speed.
For some patients, symptom improvement can occur much faster than with conventional antidepressant medications.
That does not mean everyone responds.
And it does not mean a rapid response will necessarily last.
Rapid Doesn't Mean Permanent
One of ketamine's most impressive characteristics is also one of the easiest to misunderstand.
A rapid antidepressant effect and a durable antidepressant effect are different questions.
Some people respond and later relapse.
Some receive repeated or maintenance treatments.
Some do not respond adequately in the first place.
Researchers continue to investigate how best to sustain response, whether psychotherapy can extend benefits, what maintenance strategies are appropriate and whether biomarkers can identify who is most likely to respond.
This distinction is central to understanding ketamine:
How quickly something works tells us very little about how long it will work.
What About Suicidal Thoughts?
Ketamine research has also reported rapid reductions in suicidal ideation in some clinical studies.
But regulatory language requires precision.
Spravato is approved for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior when administered with an oral antidepressant.
Its FDA labeling explicitly states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated.
Those statements may initially sound contradictory.
They aren't.
Improving depressive symptoms in someone experiencing a suicidal crisis is not equivalent to proving that a medication prevents suicide.
Beyond Depression
Once ketamine demonstrated rapid psychiatric effects, researchers began asking whether its unusual pharmacology might matter across disorders that share features such as:
rigid thinking,
maladaptive learning,
anhedonia,
fear,
compulsivity,
stress dysregulation,
or disrupted reward processing.
Some of those investigations have now reached randomized human trials.
Others are just beginning.
The most useful way to understand this landscape is not as a list of diseases ketamine “treats.”
It is as a series of evidence horizons.
PTSD: Meaningful Human Evidence, Still Developing
Post-traumatic stress disorder is among the more extensively investigated conditions beyond depression.
A 2026 systematic review identified seven randomized controlled studies of intravenous ketamine for PTSD involving 323 participants.
Some trials demonstrated meaningful reductions in PTSD symptoms compared with control conditions, while other findings were less conclusive.
The reviewers characterized ketamine as promising while emphasizing the relatively small and heterogeneous evidence base.
Researchers are also studying ketamine in conjunction with psychotherapy.
That raises an important question.
Could temporarily altering fear processing, psychological flexibility or neuroplasticity make traumatic memories more amenable to therapeutic work?
Possibly.
But PTSD is not currently an FDA-approved psychiatric indication for racemic ketamine or Spravato.
Human evidence: meaningful but developing.
Unanswered question: can ketamine produce durable PTSD improvement, and what role does psychotherapy play in sustaining it?
OCD: Can a Rigid Pattern Become Temporarily Flexible?
Obsessive-compulsive disorder presents a particularly interesting test of the neuroplasticity hypothesis.
OCD involves persistent intrusive thoughts and repetitive behavioral patterns that can be extraordinarily resistant to change.
A 2026 systematic review identified 15 ketamine studies involving 118 participants, including three randomized trials.
Some randomized studies reported rapid reductions in obsessive-compulsive symptoms after IV ketamine, but benefits from ketamine alone were often short-lived.
Studies combining ketamine with exposure and response prevention, a well-established behavioral therapy for OCD, have raised the possibility that temporarily increased psychological or neural flexibility might help therapeutic learning persist longer.
The numbers remain small.
But conceptually, the research is important.
Perhaps the therapeutic opportunity is not simply:
ketamine reduces a symptom.
Perhaps in some disorders it is:
ketamine temporarily changes the conditions under which new learning can occur.
That question connects directly with our exploration in The Window of Opportunity.
Anxiety: A Symptom Is Not a Diagnosis
Ketamine has also been associated with reductions in anxiety symptoms.
But “anxiety” describes both a symptom and a family of distinct psychiatric disorders.
A person with depression may experience severe anxiety.
So may someone with PTSD.
OCD.
Chronic pain.
A life-threatening illness.
Or a primary anxiety disorder.
Evidence that ketamine reduces anxiety symptoms in one of those populations does not automatically establish ketamine as a treatment for every anxiety disorder.
This is a recurring problem in discussions of emerging medicine:
symptom improvement is sometimes mistaken for proof of a new indication.
Research into ketamine's anxiolytic effects is promising.
The clinical meaning depends heavily on which population is being studied.
Addiction: A Paradox Worth Investigating
Ketamine presents an unusual question in addiction medicine.
The drug itself has misuse and dependence potential.
Yet researchers are investigating whether carefully controlled ketamine administration might help treat substance-use disorders.
A 2025 systematic review identified 14 studies involving 551 participants, examining alcohol, cocaine, opioid and cannabis use disorders.
Some studies reported reductions in craving, withdrawal or substance use and improvements in abstinence.
Half of the included studies combined ketamine with psychotherapy.
But study designs, doses, psychological interventions and outcome measures varied considerably.
The evidence is intriguing rather than definitive.
And the apparent paradox makes the research particularly important:
Can a drug capable of misuse, under entirely different conditions, become part of treating addiction?
Context may matter enormously.
Eating Disorders: Could Flexibility Matter Here Too?
Eating disorders—particularly anorexia nervosa—can involve extraordinary cognitive and behavioral rigidity.
Patients may intellectually understand that their behaviors are dangerous while finding entrenched patterns exceptionally difficult to change.
That has made ketamine scientifically interesting.
Could its effects on mood, learning, reward processing or neuroplasticity help loosen pathological patterns sufficiently for established eating-disorder treatment to work differently?
At present, we do not know.
A review of ketamine in eating disorders found encouraging observations but emphasized that much of the evidence consisted of case reports and case series, particularly involving anorexia nervosa.
A 2025 systematic review of pharmacological treatment for depression in underweight people similarly found ketamine represented largely by low-quality case-level evidence rather than definitive randomized trials.
Researchers are nevertheless beginning to investigate the area more systematically.
A 2025 study evaluated the safety of subanesthetic ketamine among 104 patients receiving higher levels of eating-disorder care, adding useful safety data to an area where malnutrition and medical complexity create particular concerns.
Controlled feasibility research has also been developing around ketamine for anorexia nervosa accompanied by depression.
Human evidence: early.
Unanswered question: could ketamine help make deeply entrenched cognitive and behavioral patterns more amenable to established eating-disorder treatment?
Sleep: More Than a Side Effect?
Sleep may turn out to be one of the more interesting pieces of the ketamine story.
Depression and sleep disruption are closely intertwined.
Insomnia can worsen depression.
Depression can disrupt sleep.
Circadian rhythms influence mood, cognition and physiology.
A 2026 systematic review examined 26 studies involving 1,694 people with major depressive disorder or bipolar disorder.
Ketamine was associated with favorable changes in subjective sleep quality.
The review also found preliminary evidence that baseline sleep disturbance and early improvements in sleep might help predict antidepressant response.
Possible effects on objective sleep and circadian measures were also identified, although the authors emphasized that evidence there remains limited.
This does not establish ketamine as a treatment for primary insomnia.
The more interesting possibility is that sleep and circadian regulation may be connected to the mechanisms through which ketamine affects mood.
That turns sleep from a secondary outcome into a potentially important clue.
Human evidence: meaningful within mood-disorder populations.
Not established: ketamine as a general treatment for insomnia.
Unanswered question: is improved sleep simply a consequence of improved mood—or part of the mechanism producing it?
Chronic Pain: An Older Story Than Psychiatric Ketamine
Ketamine's relevance to pain did not emerge from psychedelic psychiatry.
Its effects on NMDA-receptor signaling have made it a longstanding subject of research in anesthesia and pain medicine.
Ketamine has been used and investigated across perioperative pain, neuropathic pain and certain severe chronic pain conditions.
Its role varies substantially by condition and clinical context, and chronic administration raises different risk-benefit questions from short psychiatric protocols.
This area deserves recognition because it reminds us that ketamine is not simply an “antidepressant discovered by accident.”
It is a pharmacologically complex drug with effects across several neural systems.
Then the Question Becomes Bigger
Depression.
PTSD.
OCD.
Addiction.
Eating disorders.
Sleep.
Pain.
All can plausibly intersect with glutamatergic signaling, learning, stress physiology or neuroplasticity.
But researchers are now asking a much more ambitious question.
Could ketamine matter in disorders where the problem is not primarily psychiatric at all?
Alzheimer's, Dementia and Mild Cognitive Impairment
This is where scientific enthusiasm needs particularly careful boundaries.
There are really two different questions.
The first is relatively grounded:
Could ketamine treat depression occurring in people who also have cognitive impairment or dementia?
The second is far more speculative:
Could ketamine affect the neurodegenerative disease itself?
Those should never be conflated.
In 2026, researchers reported results from KET-MCI, a pilot study involving 13 older adults with major depression and mild cognitive impairment.
Participants received a single IV ketamine infusion.
The primary purpose was to examine safety and tolerability.
No serious adverse events occurred, and researchers observed substantial short-term improvement in depressive symptoms, with improvement persisting for some participants at one month.
But the study was open-label, involved only 13 people and was not designed to establish ketamine as a treatment for cognitive decline or Alzheimer's disease.
That distinction is essential.
The study asks whether ketamine might be usable for depression in people who also have cognitive impairment.
It does not show that ketamine reverses Alzheimer's disease.
Could Ketamine Treat Neurodegeneration Itself?
This is a much earlier frontier.
Researchers have proposed potential mechanisms involving:
glutamatergic signaling,
synaptic plasticity,
BDNF-related pathways,
neuroinflammation,
and neuronal resilience.
Animal and laboratory research has therefore explored ketamine or related compounds in models relevant to Alzheimer's disease, Parkinson's disease, stroke and other neurological conditions.
Mechanistically, this is intriguing.
Clinically, it remains highly uncertain.
A treatment that temporarily promotes aspects of synaptic plasticity is not automatically a treatment that prevents neurons from degenerating.
And a molecule that improves depression in someone with Alzheimer's disease has not necessarily changed the course of Alzheimer's disease.
Those are fundamentally different outcomes.
At present, ketamine should not be described as an established disease-modifying treatment for Alzheimer's, Parkinson's or another neurodegenerative disorder.
The scientifically interesting question is whether some of the mechanisms that made ketamine important in psychiatry could eventually prove useful elsewhere.
That remains a research question.
Neuroplasticity Is Not the Same as Neuroregeneration
This distinction deserves emphasis.
“Neuroplasticity” has become one of the most overused words in emerging mental-health medicine.
It broadly refers to the nervous system's capacity to change its structure, function or connections in response to experience and biological signals.
That is not the same thing as:
regrowing a damaged brain
or
reversing neurodegenerative disease.
Ketamine has been associated with molecular and synaptic processes relevant to plasticity.
That makes neurological applications scientifically plausible enough to investigate.
It does not establish neuroregeneration.
The distinction between those two concepts may determine whether future neurological applications prove transformative—or disappointing.
What About Cognition?
Ketamine's relationship with cognition is equally complicated.
During acute administration, ketamine can temporarily alter attention, memory, perception and cognition.
Yet depression itself can impair cognitive function, so successful treatment of depression may subsequently improve some cognitive domains.
A 2026 systematic review of IV ketamine in treatment-resistant depression examined approximately 900–1,180 participants across 21 studies. Some cognitive domains, particularly processing speed and working memory, showed improvement in multiple studies, while results for other domains were mixed.
This is very different from saying:
ketamine is a cognitive enhancer.
The effects depend on timing, population, dose, illness and what aspect of cognition is being measured.
Ketamine + Psychotherapy
One of the biggest unresolved questions is whether ketamine should be understood purely as a pharmacological treatment.
Some clinical models combine ketamine with psychotherapy.
The rationale varies.
Ketamine may temporarily reduce depressive symptoms enough to make psychological work possible.
It may increase flexibility.
It may alter emotional processing.
It may create an unusual subjective state that becomes meaningful in therapy.
Or psychotherapy may help translate a temporary pharmacological change into longer-lasting behavioral change.
Research remains heterogeneous.
Different studies use different therapies, populations, doses, routes and timing.
This makes it difficult to determine whether “ketamine-assisted psychotherapy” represents one reproducible intervention or a family of substantially different approaches.
The question nevertheless deserves serious study.
If ketamine temporarily creates a window of opportunity, what happens inside that window may matter.
Does the Altered State Matter?
There is another unresolved possibility.
Perhaps ketamine's effects are primarily pharmacological.
Perhaps dissociation and psychedelic-like experiences are incidental.
Or perhaps some qualities of the altered state contribute to therapeutic change in certain people.
Research remains mixed.
Conventional measures of ketamine-related dissociation do not consistently predict antidepressant outcomes.
Other studies examining mystical-type, psychedelic-like or personally meaningful experiences have found associations with subsequent improvement.
Association does not establish causation.
But it raises a deeper question:
Could two people receive the same molecule while psychologically receiving very different treatments?
We explore that question separately in Beyond Reality: Which Parts of the Ketamine Experience Matter?
How Might Ketamine Work?
There is no single accepted sentence that fully explains ketamine's antidepressant action.
Its pharmacology begins with effects involving NMDA-type glutamate receptors, but downstream consequences appear to involve multiple interacting processes.
Research has implicated:
glutamatergic signaling
AMPA receptor activity
BDNF-related signaling
mTOR-associated pathways
synaptic plasticity
and broader network-level changes.
Researchers continue to debate which mechanisms are necessary, which are downstream effects and how they interact with psychological experience.
So the familiar phrase:
“Ketamine grows new neural pathways”
is an oversimplification.
A more defensible statement is:
Ketamine can influence molecular and synaptic processes associated with neuroplasticity, which may contribute to its rapid antidepressant effects.
Exactly how those processes translate into changes in mood remains an active area of research.
Where Enthusiasm Gets Ahead of Evidence
Ketamine occupies an unusual position in medicine.
It is an old generic anesthetic.
It is also a Schedule III controlled substance.
It is used off-label in psychiatry.
One of its molecular components has become an FDA-approved psychiatric medication.
It can produce profound alterations in consciousness.
And research now spans psychiatry, pain, sleep, cognition and neurological disease.
That combination invites hype.
A positive mouse experiment becomes:
“Ketamine may regenerate the brain.”
A case series becomes:
“Ketamine treats anorexia.”
Improved sleep among depressed patients becomes:
“Ketamine cures insomnia.”
Improved depression in someone with mild cognitive impairment becomes:
“Ketamine treats Alzheimer's.”
Those transformations are not scientifically justified.
The frontier is interesting enough without exaggerating it.
Risks Matter Too
No serious discussion of ketamine's potential is complete without discussing risk.
The current FDA label for Ketalar warns about cardiovascular effects including elevated blood pressure and pulse, emergence reactions, respiratory depression under certain circumstances, and drug-induced liver injury. Ketamine is a Schedule III controlled substance.
Repeated or heavy ketamine exposure—particularly in patterns associated with misuse—has also been associated with serious urinary tract and bladder problems, gastrointestinal complications, cognitive effects and dependence.
At the same time, the safety profile observed in medically supervised psychiatric treatment should not simply be equated with chronic recreational misuse.
A 2026 systematic review of longer-term ketamine and esketamine treatment for treatment-resistant depression found serious treatment-attributable adverse events to be uncommon in the available literature, while also emphasizing limitations and heterogeneity in long-term safety monitoring.
The appropriate conclusion is neither:
ketamine is dangerous
nor
ketamine is harmless.
Risk depends on dose, route, frequency, medical condition, concomitant substances, treatment setting and pattern of use.
Three Evidence Horizons
The easiest way to understand ketamine research may be to separate it into three broad horizons.
More Developed Human Clinical Evidence
Depression and treatment-resistant depression
This is where modern psychiatric evidence is most mature.
Intranasal esketamine has FDA-approved psychiatric indications.
Racemic ketamine has substantial off-label clinical research, particularly involving IV administration.
Emerging Human Clinical Evidence
Research is developing in areas including:
PTSD
OCD
substance-use disorders
anxiety symptoms and selected anxiety disorders
eating disorders
sleep and circadian dysfunction within mood disorders
ketamine-assisted psychotherapy
Evidence varies substantially even within this group.
“Emerging” does not mean “established.”
Experimental Frontier
Researchers are exploring questions involving:
Alzheimer's disease and related dementias
mild cognitive impairment
Parkinson's disease
other neurodegenerative conditions
neuroinflammation
neuroprotection
cognitive function
stroke and neurological recovery
In many of these areas, mechanistic reasoning and animal research substantially exceed human clinical evidence.
That gap matters.
What We Know
Ketamine is an established anesthetic with a long medical history.
Racemic ketamine has substantial human evidence supporting rapid antidepressant effects, particularly in treatment-resistant depression, although psychiatric use remains off-label in the United States.
Intranasal esketamine has FDA-approved indications for treatment-resistant depression and depressive symptoms in adults with MDD accompanied by acute suicidal ideation or behavior under the conditions specified in its labeling.
Clinical research beyond depression includes PTSD, OCD, substance-use disorders, eating disorders and other psychiatric conditions, but evidence varies considerably in quantity and quality.
Ketamine may influence sleep and circadian processes in people with mood disorders, although it is not established as a general treatment for insomnia.
Early research suggests ketamine can be studied in older adults with depression and mild cognitive impairment, but this does not establish ketamine as a treatment for Alzheimer's disease or cognitive decline.
Ketamine influences biological processes associated with neuroplasticity.
That does not mean it has been demonstrated to regenerate the human brain or reverse neurodegenerative disease.
What We Don't Know
We do not know which patients are most likely to respond to ketamine.
We do not fully understand why some responses occur within hours.
We do not know the optimal long-term strategy for every psychiatric use.
We do not know how important neuroplasticity is relative to other biological mechanisms.
We do not know how much the subjective altered-state experience contributes to therapeutic outcomes.
We do not know whether psychotherapy reliably extends or amplifies ketamine's effects across disorders.
We do not know whether improvements in sleep help cause antidepressant response or primarily accompany it.
We do not know whether early signals in eating disorders will survive larger controlled trials.
And we do not know whether ketamine's effects on synaptic plasticity will eventually translate into useful treatments for neurodegenerative disease.
The Question That Remains
Ketamine's significance may ultimately extend beyond the number of diagnoses for which it proves useful.
It has already forced researchers to reconsider how quickly severe psychiatric symptoms can change.
It has renewed interest in glutamate after decades dominated by monoamine-based antidepressant theories.
It has intensified research into adult neuroplasticity.
It has reopened questions about the relationship between medicine and subjective experience.
And now it is pushing into fields ranging from sleep to addiction, eating disorders and neurological disease.
Some of those possibilities will survive rigorous testing.
Others probably won't.
That is how science is supposed to work.
The challenge is resisting the temptation to convert biological plausibility into clinical certainty—or early promise into established treatment.
So perhaps the most useful question isn't:
What else can ketamine treat?
It is:
Which of ketamine's promises will still be standing when the evidence catches up with the enthusiasm?
Sources & Further Reading
This article draws on current FDA prescribing information and peer-reviewed systematic reviews and clinical studies concerning ketamine and esketamine in depression, PTSD, OCD, substance-use disorders, eating disorders, sleep and circadian function, cognition and mild cognitive impairment.
Evidence varies substantially by condition. Inclusion of a condition in this article means it is the subject of scientific investigation—not that ketamine has been demonstrated to treat it.
Disclosure
The founder and publisher of The Brazen Word is also a founder of Ketamine Lounge, a healthcare business offering ketamine-related services. This relationship is disclosed because it is directly relevant to the subject of this article.
The scientific and regulatory claims in this article are based on external research and regulatory sources. Ketamine Lounge's commercial interests do not determine the editorial conclusions presented here.
Editorial Note
The terms established, emerging and experimental in this article describe the general maturity and type of evidence discussed; they are not clinical recommendations or formal evidence grades.
References to neuroplasticity should not be interpreted as evidence that ketamine regenerates damaged brain tissue or reverses neurodegenerative disease.
Medical Disclaimer
This article is provided for informational and educational purposes only and is not intended as medical advice, diagnosis or treatment.
Racemic ketamine is FDA-approved as an anesthetic and is not FDA-approved for psychiatric treatment. Intranasal esketamine has separate FDA-approved psychiatric indications and is subject to specific administration, monitoring and safety requirements.
Treatment decisions concerning ketamine or esketamine should be made by appropriately qualified healthcare professionals after consideration of an individual's medical and psychiatric circumstances.
